



TB CARE I

TB CARE I - Botswana

Year 4

Quarterly Report

October – December 2013

January 30, 2014

Table of Contents

| | |
|---|----------|
| 1. QUARTERLY OVERVIEW | 3 |
| 2. YEAR 4 TECHNICAL OUTCOMES AND ACTIVITY PROGRESS | 4 |
| 2.1 Universal Access | 4 |
| 2.2 Laboratories | 4 |
| 2.4 PMDT | 5 |
| 3. TB CARE I'S SUPPORT TO GLOBAL FUND IMPLEMENTATION IN YEAR 4 | 6 |
| 4. MDR-TB CASES DIAGNOSED AND STARTED ON TREATMENT IN COUNTRY | 7 |
| 5. TB CARE I-SUPPORTED INTERNATIONAL VISITS (TECHNICAL AND MANAGEMENT-RELATED TRIPS) | 8 |
| 6. FINANCIAL OVERVIEW | 9 |

1. Quarterly Overview

| | |
|--------------------|--|
| Country | Botswana |
| Lead Partner | KNCV |
| Coalition Partners | None |
| Other partners | CDC BOTSWANA, I-TECH, ACHAP, U-PENN, WHO |
| Workplan timeframe | Oct 2013-Sep 2014 |
| Reporting period | Oct – Dec 2013 |

Most significant achievements:

The in-country Senior Technical advisor participated in a data collection exercise in two districts for the evaluation of community TB Care (CTBC) research project to assess how CTBC in Botswana has contributed to the attainment of TB control efforts in the country. This research will guide the NTP to adopt an appropriate CTBC approach to be scaled up, taking into consideration the decline in funding in the near future.

TB CARE I in collaboration with partners supported the roll out of Gene Xpert to 6 facilities of planned 14 (Rakops primary hospital, Letlhakane primary hospital, Nata Clinic, Tutume primary hospital, Mahalapye district hospital and Kasane primary hospital) and trained 21 laboratory technicians (F=11). The instruments are being used to improve case detection among the MDR risk group and HIV positive TB suspects. TB CARE I will continue to support the NTP with further roll out of 8 more instruments in the country.

The in-country Senior Technical Advisor supported the NTP in the finalization of agendas, presentations and opening speech for the combined Team TB/HIV and ARV site managers national biannual review meeting. This 3-day meeting of TB and HIV managers focused on progress of implementation, challenges and way-forward for TB/HIV activities. Of importance was the recommendation to scale up coverage of gastric aspirate collection for optimizing diagnosis of childhood TB. There have been challenges with high contamination at the NTRL with particular reference to gastric aspirates, this process will need further support from TB CARE I to ensure that the recommendations add value.

TB CARE I supported a successful Green Light Committee mission to Botswana with co-ordination of the mission's visits and meeting with partners. TB CARE I also supported the MDR clinical meeting which was held in Mahalapye. The meeting was well attended by a total of 57 participants including in-country partners with representation from all the TB treatment sites.

The Chief Medical laboratory technician supported the district laboratories with an on-site supportive visits to strengthening external quality assurance and implementation of acid fast bacilli smear microscopy in Selebi Phikwe district hospital, Mmadinare primary hospital, Bobonong primary hospital, Diagnofirm private laboratories S/Phikwe, and Gaborone, Bokamoso private hospital laboratory, GPH lancet laboratories, Med lab diagnostics, Tutume primary hospital and Gweta primary hospital laboratory. Site assessments were conducted and recommendations on identified gaps were shared with district laboratory teams. Two key issues noted were that recording and reporting still remain a challenge in the network and new members of staff who have been recently hired will need AFB microscopy training.

The NTRL quality management system was supported with the annual review of safety SOPs and also with technical input in provision of feedback to the South Africa National Accreditation System (SANAS) for addressing recommendations of another successful annual SANAS external audit, whereby the NTRL has retained its status as an ISO 15189 accredited laboratory.

Technical and administrative challenges:

There are continued challenges with supplies at the NTRL; however, the MoH is now in the process of centralizing all supply procurement to the Central Medical Stores which is expected to be fully functional by the beginning of April 2014. There were delays in the roll out of Gene Xpert due to limited staffing at the NTP and the NTRL. Two training- of-trainers sessions were conducted for staff at the NTRL to further increase the pool of GeneXpert trainers.

2. Year 4 technical outcomes and activity progress

2.1 Universal Access

| Code | Outcome Indicators and Results | | Actual Year 3 or Baseline Result | Expected End of Year 4 Result | Result to date ¹ | | Comments |
|---------------------|---------------------------------|---|--|-------------------------------|-----------------------------|---------------------|----------|
| 1.2.9 | Population covered with CB-DOTS | | 81% (1,650,964) | 90% (1,834,405) | Measured annually | | |
| Activity Code (***) | Lead Partner | TB CARE Year 4 Planned Activities | Cumulative Progress as of the quarter's end | Planned Month | | Status ² | |
| | | | | Start | End | | |
| 1.2.1 | KNCV | Increase coverage of CTBC In country Senior Technical Advisor in collaboration with NTP supports enhanced Community DOTS implementation strategy from existing guidelines and National Strategic plan to increase coverage of CTBC from 81% to 90%. | Participated in the data collection for the CTBC evaluation. This will aid in streamlining and advocating for a more targeted CTBC approach. | Oct 13 | Sep 14 | Ongoing | |

2.2 Laboratories

| Code | Outcome Indicators and Results | Actual Year 3 or Baseline Result | Expected End of Year 4 Result | Result to date | Comments |
|-------|--|----------------------------------|-------------------------------|----------------|--|
| 2.1.2 | Laboratories with working internal and external QA programs for smear microscopy and culture/DST | 100%(52/52) (2013) | 100%(52/52) (2014) | 52/52 | Panel testing sent with an average 97.3% pass mark. Lab techs who failed will be recalled for retraining in Gaborone |
| 2.3.1 | Diagnostic sites offering advanced | 20 Gene Xpert(2012) | 34 Gene | 26 | |

¹ If results are not available, write “Measured annually” or “Not yet measured” and say when the data are estimated to be available. Not all indicators can be measured quarterly.

² Status options: Pending (the activity has not yet started, but is not delayed); Ongoing (the activity has started and is in process); Completed (all sub-activities and outputs are complete); Postponed (the start or completion of this activity has been delayed, but will still be completed by the end of the workplan year); Cancelled (the activity, which may or may not have started, will not be completed by TB CARE I.)

| | technologies for TB or drug-resistant TB | | | Xpert(2014) | | |
|---------------------------|--|---|--|---------------|--|---------|
| 2.1.4 | NRL maintains ISO accreditation Description | | Yes(2013) | Yes(2014) | Results available in quarter 4 report | Ongoing |
| Activity Code (***) | Lead Partner | TB CARE Year 4 Planned Activities | Cumulative Progress as of the quarter's end | Planned Month | | Status |
| | | | | Start | End | |
| 2.1.1 | KNCV | Support NTRL and TB laboratory network through training in smear microscopy and technical input into quality assurance and external quality assurance | Panel Tests were sent out to all labs with a 97.3% average pass mark. Lab techs who failed will be recalled for retraining in Gaborone | Oct 13 | Sep 14 | Ongoing |
| 2.1.2 | KNCV | Support the NTRL to maintain accreditation | SOP review conducted for safety standard operating procedures | Oct 13 | Sep 14 | Ongoing |
| 2.3.1 | KNCV | Support roll out of Gene Xpert | Gene Xpert rolled out to 6 sites | Oct 13 | Sep 14 | Ongoing |
| 2.3.2 | KNCV | Strengthen Culture and DST at NTRL | TA mission scheduled for 1st week of February | Oct 13 | Sep 14 | Ongoing |

2.4 PMDT

| Code | Outcome Indicators and Results | | Actual Year 3 or Baseline Result | Expected End of Year 4 Result | Result to date | Comments |
|---------------------------|---|---|---|-------------------------------------|--|----------|
| 4.1.3 | MDR TB patients who have completed the full course of MDR TB treatment regimen and have a negative sputum culture | | 80% | 80% | Results available in quarter 4 report | |
| Activity Code (***) | Lead Partner | TB CARE Year 4 Planned Activities | Cumulative Progress as of the quarter's end | Planned Month | | Status |
| | | | | Start | End | |
| 4.1.1 | KNCV | Support MDR treatment sites | | Oct 13 | Sep 14 | Pending |
| 4.1.2 | KNCV | Support biannual MDR meeting and GLC missions | One MDR clinical meeting held and GLC mission supported | Oct 13 | Sep 14 | Ongoing |

3. TB CARE I's support to Global Fund implementation in Year 4

Current Global Fund TB Grants

| Name (i.e. Round 10 TB) | Average rating* | Current rating | Total approved amount | Total dispersed to date |
|-------------------------|-----------------|----------------|-----------------------|-------------------------|
| TFM | A2 | B1 | 2776241 | |
| | | | | |
| | | | | |

* Since January 2010

In-country Global Fund status - key updates, challenges and bottlenecks

Botswana starts preparation for the development of a concept note for the new funding mechanism. The CCM has indicated that it will submit a joint proposal for TB, HIV and Malaria. Two MoH staff including the GF manager will attend the National strategic plan (NSP) workshop in France, arranged by WHO, in preparation for aligning the national strategic plan (NSP) with the GFATM new funding model (NFM) requirements.

TB CARE I & Global Fund - TB CARE I involvement in GF support/implementation and effect of GF on the TB CARE I workplan

TB CARE I plans to support the NTP with the development of the concept note through in-country support and from The Hague.

4. MDR-TB cases diagnosed and started on treatment in country

| Quarter | Number of MDR cases diagnosed | Number of MDR cases put on treatment | Comments: |
|--------------|-------------------------------|--------------------------------------|-----------|
| Total 2010 | 106 | 92 | |
| Total 2011 | 46 | 44 | |
| Total 2012 | 51 | 44 | |
| Jan-Mar 2013 | 19 | 14 | |
| Apr-Jun 2013 | 9 | 9 | |
| Jul-Sep 2013 | 12 | 12 | |
| Oct-Dec 2013 | 18 | 18 | |
| Total 2013 | 58 | 53 | |

5. TB CARE I-supported international visits (technical and management-related trips)

| # | Partner | Activity Code | Name | Purpose | Planned month, year | Status | Dates completed | Additional Remarks (Optional) |
|---|---------|---------------|---------------------|--|---------------------|---------|-----------------|-------------------------------|
| 1 | KNCV | 1.2.1 | Jerod Scholten | Supervision and Monitoring of local office | July 2014 | Pending | | |
| 2 | KNCV | 2.3.2 | Valentina Anisimova | Technical Assistance | March 2014 | Pending | | |
| Total number of visits conducted (cumulative for fiscal year) | | | | | | 0 | | |
| Total number of visits planned in workplan | | | | | | 2 | | |
| Percent of planned international consultant visits conducted | | | | | | 0 | | |